Welcome to Amgen Care

You are leaving Amgencare.co.uk website and entering another Amgen website

You are leaving Amgencare.co.uk website and entering another Amgen website

You are now leaving Amgencare.co.uk
Amgen does not endorse or accept liability for sites controlled by third parties

Return to previous page Continue

Welcome to Amgen Care

This site is intended for UK patients

Support for patients

This site is designed to provide information to patients who have been prescribed an Amgen® medicine. Should you have any concerns or questions regarding your treatment, please speak to your doctor or nurse.

Please select one of the options below:

I am, or I care for, an AMGEVITA® (adalimumab) patient.
Enter site
I am, or I care for a Lumykras® ▼ (sotorasib) patient.
Enter site
I am, or I care for, a Repatha® (evolocumab) patient.
Enter site
I am, or I care for, a Neulasta® (pegfilgrastim) patient.
Enter site
I am, or I care for, a Nplate® (romiplostim) patient.
Enter site
I am, or I care for, a XGEVA® (denosumab) patient.
Enter site
I am, or I care for, an OTEZLA® (apremilast) patient.
Enter site
I am, or I care for, a Vectibix® (panitumumab) patient.
Enter site
I am, or I care for, a WEZENLA®▼ (ustekinumab) patient.
Enter site
I am a member of the general public and have not been prescribed any of these Amgen® medicines.
Enter site

Safety information

▼ This medicinal product is subject to additional monitoring.
Reporting of side effects
If you get side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store. By reporting side effects you can help provide more information on the safety of this medicine. Side effects should also be reported to Amgen Ltd on +44 (0) 1223 436441.